Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

  • Amir Ansaripour
  • Carin A. Uyl-de Groot
  • W. Ken Redekop
Letter to the Editor

Notes

Compliance with Ethical Standards

Funding

No sources of funding were received for the preparation of this response.

Conflict of interest

Amir Ansaripour, Carin A. Uyl-de Groot, and W. Ken Redekop have no conflicts of interest directly relevant to the content of this response.

References

  1. 1.
    Ansaripour A, Uyl-de Groot C, Redekop WK. Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. Pharmacoeconomics. 2018;36:91–103.CrossRefPubMedGoogle Scholar
  2. 2.
    Gershon N, Berchenko Y. Optimality, future costs and terminal costs. Pharmacoeconomics. 2018.Google Scholar
  3. 3.
    Versteegh M, Knies S, Brouwer W. From good to better: new Dutch guidelines for economic evaluations in healthcare. Pharmacoeconomics. 2016;34:1071–4.CrossRefPubMedGoogle Scholar
  4. 4.
    The World Bank. In: GDP per capita (current US$). 2015. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 20 Oct 2015.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute for Medical Technology Assessment, Erasmus School of Health Policy and ManagementErasmus University RotterdamRotterdamThe Netherlands

Personalised recommendations